Adlai Nortye Ltd. has submitted a clinical trial notification (CTN) to Australia’s Therapeutic Goods Administration (TGA) and received approval from the Human Research Ethics Committee (HREC) to initiate a phase I trial of AN-4035 in patients with CEACAM5-enriched RAS-addicted solid tumors.